ArcelorMittal SA vs Stryker Corporation — how do they compare? ArcelorMittal SA trades at $64.11 (market cap $45.70B), while Stryker Corporation trades at $276.5 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 2.3× ArcelorMittal SA's market cap, and Stryker Corporation pays the higher dividend (1.27%). Which is the better fit depends on your goals — on Pluang, investors hold ArcelorMittal SA for 36 Days and Stryker Corporation for 20 Days on average.
| MT | SYK | |
|---|---|---|
Market Cap | $45.70B | $106.24B |
Volume | 1,964,621 | 2,982,001 |
Sector | Basic Materials | Health |
52-Week High | $78.74 | $388.35 |
52-Week Low | $36.91 | $269.75 |
Typical Hold Time | 36 Days | 20 Days |
Enterprise Value | $55.27B | $117.70B |
Dividend Yield | 0.98% | 1.27% |
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $62.32, down 4.4% today, with technical indicators signaling bearish momentum. The stock shows mixed fundamentals with revenue declining from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Recent news highlights operational disruptions at its Ukrainian plant with a potential $1B impairment charge, while analyst consensus remains positive with a $74.33 price target.
The outlook is cautious due to geopolitical risks and declining revenue trends, but valuation metrics appear reasonable with P/E of 26.2 and P/B of 0.86. Investment opportunity exists if European operations stabilize and growth projects deliver, though investors face headwinds from steel demand volatility and ongoing Ukraine-related impairments.
Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.
Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →